Author

Junwu Shen

Observed names: JunWu Shen, Shen, Junwu

Institution: Nuvalent, Inc. (United States)

Observed institutions: Bayer (United States), Nuvalent, Inc. (United States), Takeda Oncology (United States)

OpenAlex ID: A5113059947

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

2019 · Matthew Smith, Chris Parker, et al. · The Lancet Oncology · 423

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

2015 · Yesim Aydinok, Antonis Kattamis, et al. · Blood · 88

Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine

2014 · Dudley J. Pennell, John B. Porter, et al. · American Journal of Hematology · 53

ALTA-2: Phase II Study of Brigatinib in Patients with ALK-Positive, Advanced Non-Small-Cell Lung Cancer Who Progressed on Alectinib or Ceritinib

2021 · Edward S Kim, Fabrice Barlesi, et al. · Future Oncology · 14

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

2013 · Yesim Aydinok, Antonis Kattamis, et al. · Blood · 11

ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer.

2016 · Matthew R. Smith, Chris C. Parker, et al. · Journal of Clinical Oncology · 7

Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.

2025 · Sanjay Popat, Benjamin J. Solomon, et al. · Journal of Clinical Oncology · 6

Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors

2023 · Jessica J Lin, Melissa Johnson, et al. · Molecular Cancer Therapeutics · 5

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

2022 · Karen L. Reckamp, Huamao M. Lin, et al. · Current Medical Research and Opinion · 5

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

2013 · Dudley J Pennell, John B Porter, et al. · Blood · 4

Finite mixture regression models and applications

2011 · Shen, Junwu · Rutgers University Community Repository (Rutgers University) · 1

PP01.41: Patient-Reported Outcomes and Health-Related Quality of Life of TKI Pre-Treated and TKI-Naïve Patients With Advanced ROS1-Positive NSCLC Treated with Zidesamtinib: Examination of ARROS-1 Phase 2 Trial Data

2026 · Shauna McManus, Melissa Laurie, et al. · Journal of Thoracic Oncology

PP01.32: Zidesamtinib in Patients with Advanced/Metastatic ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Tyrosine Kinase Inhibitors (TKI): Pivotal Efficacy and Safety Data from the Phase 1/2 ARROS-1 Trial

2026 · Stephen V. Liu, Alexander E. Drilon, et al. · Journal of Thoracic Oncology

Bmet-35ceritinib in Alk+ Nsclc Metastatic to Brain And/or Leptomeninges: the Ascend-7 Study

2015 · Patrick Yung Wen, Fabrice Barlesi, et al. · Neuro-Oncology

Works count: 15

Citation count: 617

H-index: 6

I10-index: 5